WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018057506) COMPOSITIONS AND METHODS FOR CHARACTERIZING SOLID TUMORS RESPONSIVENESS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/057506    International Application No.:    PCT/US2017/052246
Publication Date: 29.03.2018 International Filing Date: 19.09.2017
IPC:
A61K 31/7088 (2006.01), A61P 35/00 (2006.01), C12N 15/113 (2010.01)
Applicants: MEDIMMUNE, LLC [US/US]; One MedImmune Way Gaithersburg, MD 20878 (US)
Inventors: HIGGS, Brandon, W.; (US).
MOREHOUSE, Chris; (US).
BROHAWN, Philip; (US).
STREICHER, Katie; (US).
RANADE, Koustubh; (US)
Agent: MENSAH, Kwame, N.; (US).
CARROLL, Shannon; (US).
DISE, Rebecca, S.; (US).
BRASLOW, Kimberly; (US).
ALBAN, Patrick; (US)
Priority Data:
62/397,062 20.09.2016 US
Title (EN) COMPOSITIONS AND METHODS FOR CHARACTERIZING SOLID TUMORS RESPONSIVENESS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY
(FR) COMPOSITIONS ET PROCÉDÉS POUR CARACTÉRISER LA RÉACTIVITÉ DE TUMEURS SOLIDES À UNE MONOTHÉRAPIE D'ANTICORPS ANTI-PD-L1
Abstract: front page image
(EN)The present invention provides methods for selecting patients as having a solid tumor (e.g., bladder cancer, ovarian cancer, colorectal cancer, head and neck cancer, cervical cancer, renal cell carcinoma, and non-small cell lung cancer (NSCLC)) that is responsive to treatment with an anti-PD-L1 antibody, and methods of treating such patients. The method involves detecting expression of an IFNG polynucleotide and/or one or more of polynucleotide markers: CXCL9, CD274, and LAG3, in a biological sample of the patient.
(FR)La présente invention concerne des procédés de sélection de patients comme ayant une tumeur solide (par exemple, un cancer de la vessie, un cancer des ovaires, un cancer colorectal, un cancer de la tête et du cou, un cancer du col de l'utérus, un carcinome des cellules rénales et un cancer du poumon non à petites cellules (NSCLC)) qui est sensible au traitement par un anticorps anti-PD-L1, et des méthodes de traitement de tels patients. Le procédé comprend la détection de l'expression d'un polynucléotide IFNG et/ou d'un ou plusieurs des marqueurs polynucléotidiques : CXCL9, CD274 et LAG3, dans un échantillon biologique du patient.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)